Navigation Links
Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013
Date:6/19/2013

Raleigh, NC (PRWEB) June 19, 2013

Clinverse, Inc., a global technology and eclinical commerce network for clinical trials, today announced it will be exhibiting and showcasing its technology at DIA 2013 (booth #2000) in Boston, June 24-26, 2013. Clinverse’s eClinical Commerce Network is the industry’s first and only fully configurable, cloud-based clinical financial lifecycle system.

Clinverse’s patent-pending technology, ClinPay®, the flagship module within Clinverse’s eClinical Commerce Network, automates site contract set-up and management, contract term translation, investigator payments and all the GAAP accounting and financial reporting across the entire lifecycle of a clinical trial while ending the need for any post-study reconciliation. Earlier this month, Clinverse introduced ClinSpend™, a new module for aggregating and reporting compliant data to the appropriate entity responsible for OPEN PAYMENTS (formerly know as Sunshine Act) reporting.

DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. This annual meeting provides thought leaders, decision-makers and patient advocates with the opportunity to collaborate and share knowledge with the top minds in medicine.

In addition to exhibiting at DIA, Clinverse is hosting a free webcast on Wednesday, June 19 at 2:00 pm ET titled “The Sun Has Risen on the Sunshine Act: Understanding the Challenges of Complying with the National Physician Payment Transparency Program.” With over 100 attendees from throughout BioPharma already signed up to attend, the webcast will serve as a forum for attendees to learn about the requirements associated with OPEN PAYMENTS and hear best practices for compliance.

Presenters include:

  •     Steve Ayala, President and Head of Partnerships, Clinverse, Inc.
  •     John Lewis, CEO, Aggregate Spend Solutions, LLC
  •     Ami Patel, Attorney in the FDA & Life Sciences Practice Group at the international law firm of King & Spalding

To register for the webcast, visit: http://ow.ly/lJWKY..

If you are interested in scheduling a time to learn more about Clinverse’s technology while at DIA 2013, please call 1.877.325.1122 or email info(at)clinverse(dot)com.

About Clinverse, Inc.
Clinverse, Inc. is a global technology and financial services company that delivers highly secure, cloud-based financial management and payment solutions for the clinical trials industry. Founded in 2008 and headquartered in Raleigh, NC, the company delivers clinical financial solutions through the only truly collaborative and transparent financial management and payment platform. Used by leading BioPharma companies, Clinverse has developed ClinPay® FLS, a fully-configurable, game-changing SaaS-based platform which manages tens of millions of dollars in financial transactions for thousands of global sites while supporting payments in 140 different currencies. For more information, please visit http://www.clinverse.com.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10849358.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC
2. Clinverse, Inc. Introduces ClinSpend to Meet Challenges of Sunshine Act Reporting Requirements
3. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
4. In Focus with Martin Sheen Showcasing How Medication is Helping Win the Fight Against Mood Disorders
5. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
6. Positive Clinical Study Results for BSPs HyperQ Technology
7. Arizona State University engineers aim to improve performance of technology in extreme environments
8. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
9. Pitt discoveries in quantum physics could change face of technology
10. Verenium to Present at Baird Clean Technology Conference
11. Puma Biotechnology Announces Completion of Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
(Date:3/22/2017)... March 22, 2017   VWR ... of product and service solutions to laboratory ... has acquired EPL Archives, Inc., an international ... the entire regulated product research, development and ... storage and ancillary services. EPL Archives is ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation ... on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, ... of therapeutic antibodies. , To meet this demand, the team at SCIEX ...
Breaking Biology Technology:
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice Recognition ... to match it against a stored voiceprint template. ... pitch, cadence, and tone are compared to distinguish ... hardware installation, as most PCs already have a ... transactions. Voice recognition biometrics are most likely to ...
(Date:2/8/2017)... Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion in ... a compound annual growth rate (CAGR) of 24.0% through 2021. ... for synthetic biology. - Analyses of global market trends, with ... annual growth rates (CAGRs) through 2021. - Coverage of core ...
Breaking Biology News(10 mins):